Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 477 Jan 1 – Oct 25, 2026
- Disclosed funding
- $20.2B 403 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| L LightcastCompany profile Develops functional single-cell analysis tools and platforms for life science research Develops functional single-cell analysis tools and platforms for life science research | $27M | Undisclosed | Biotech | United Kingdom | Investors | |
| QB Develops therapeutics for central nervous system disorders | Undisclosed | StrategicUndisclosed | Biotech | United States | Investors | |
| VT Develops extrahepatic RNA-targeting therapeutics | $54M | Series A | Biotech | China | Investors | |
| OT Oricell TherapeuticsCompany profile Develops next-generation cell therapies for oncology and immunology Develops next-generation cell therapies for oncology and immunology | $110M | Pre-IPOUndisclosed | Biotech | China | Investors | |
| D Builds AI toxicology tools for drug development | $1.5M | Seed | Biotech | United States | Investors | |
| ST Develops next-generation bispecific ADCs for cancer treatment | $137M | Series B | Biotech | United States | Investors | |
| RL Develops first-in-class peptides for inflammatory disorders | $40M | Undisclosed | Biotech | United States | Investors Undisclosed | |
| P PetwealthCompany profile Provides at-home PCR diagnostics and AI-powered health intelligence for dogs and cats Provides at-home PCR diagnostics and AI-powered health intelligence for dogs and cats | $1.7M | Pre-SeedPre-seed | Biotech, Healthtech | United States | Investors Undisclosed | |
| KC Kytopen CorpCompany profile Develops non-viral, continuous flow cellular engineering technologies for cell therapy manufacturing Develops non-viral, continuous flow cellular engineering technologies for cell therapy manufacturing | Undisclosed | Series B | Biotech | United States | Investors | |
| SB Develops intelligent platform-driven macrocyclic peptide drug discovery | $150M | Series B | Biotech | China | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
23rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.